Indivior Pharmaceuticals Inc
HealthcareNASDAQ:INDV · NASDAQ Global Select
+$0.35 today
Vol 0.60M · Avg 2.48M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.3B of revenue converted into $251.0M of net income for the selected period. Gross margin is 83.1% and net margin is 19.0%, showing how much revenue survives after costs and taxes. EPS is $1.98, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B +4.3% | $1.2B +8.7% | $1.1B +21.3% | $901.0M +13.9% | $791.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $246.0M +6.5% | $231.0M +32.8% | $174.0M +15.2% | $151.0M +18.9% | $127.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $993.0M +3.8% | $957.0M +4.1% | $919.0M +22.5% | $750.0M +13.0% | $664.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 80.1% -0.4pp | 80.6% -3.5pp | 84.1% +0.8pp | 83.2% -0.7pp | 83.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $97.0M -9.3% | $107.0M -7.8% | $116.0M +56.8% | $74.0M +42.3% | $52.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $634.0M +2.6% | $618.0M +8.6% | $569.0M +21.3% | $469.0M +8.8% | $431.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $728.0M -21.3% | $925.0M -14.0% | $1.1B +29.4% | $831.0M +84.3% | $451.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $20.0M -31.0% | $29.0M +93.3% | $15.0M -6.3% | $16.0M -27.3% | $22.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $304.0M +261.9% | $84.0M +184.8% | -$99.0M -115.2% | -$46.0M -119.3% | $238.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 24.5% +17.5pp | 7.1% +16.1pp | -9.1% -4.0pp | -5.1% -35.2pp | 30.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $265.0M +728.1% | $32.0M +120.5% | -$156.0M -92.6% | -$81.0M -138.0% | $213.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 21.4% +18.7pp | 2.7% +17.0pp | -14.3% -5.3pp | -9.0% -35.9pp | 26.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $22.0M -4.3% | $23.0M -46.5% | $43.0M +126.3% | $19.0M +375.0% | $4.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $45.0M +9.8% | $41.0M +17.1% | $35.0M +20.7% | $29.0M +11.5% | $26.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$26.0M -44.4% | -$18.0M -357.1% | $7.0M +187.5% | -$8.0M +65.2% | -$23.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $239.0M +1607.1% | $14.0M +109.4% | -$149.0M -67.4% | -$89.0M -146.8% | $190.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 19.3% +18.1pp | 1.2% +14.8pp | -13.6% -3.8pp | -9.9% -33.9pp | 24.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $29.0M +163.6% | $11.0M +155.0% | -$20.0M +54.5% | -$44.0M -193.3% | -$15.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $210.0M +10400.0% | $2.0M +101.6% | -$129.0M -193.2% | -$44.0M -121.5% | $205.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | 16.9% +16.8pp | 0.2% +12.0pp | -11.8% -6.9pp | -4.9% -30.8pp | 25.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +11025.8% | $0 +3.4% | $0 +103.9% | -$0 -126.8% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +10833.3% | $0 +6.4% | $0 +103.8% | -$0 -128.2% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $125.0M -5.3% | $132.0M -3.9% | $137.3M -1.2% | $139.0M -4.6% | $145.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $128.0M -3.8% | $133.0M -6.2% | $141.8M +2.0% | $139.0M -9.9% | $154.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.80B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
$5.17B
Hinge Health, Inc.
NYSE:HNGE
$5.06B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.34B
Option Care Health, Inc.
NASDAQ:OPCH
$3.26B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.90B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does INDV generate?
Indivior Pharmaceuticals Inc (INDV) reported $1.24B of revenue in fiscal 2025.
Is INDV profitable?
Indivior Pharmaceuticals Inc (INDV) reported $210.00M of net income, with a net margin of 16.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.